Dedifferentiated Liposarcoma Clinical Trial
Official title:
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.
Approximately 160 patients will be randomly assigned in a 1:1 ratio to receive milademetan or trabectedin. Randomization will be stratified by the ECOG performance status (0 or 1) and number of prior treatments (≤ 2 or > 2) for the patient's liposarcoma. Patients will receive study drug (i.e., milademetan or trabectedin) until reaching unequivocal disease progression (RECIST v.1.1) as determined by the Investigator, experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. Patients may be treated beyond tumor progression if they are experiencing clinical benefit based on the assessment of the Investigator in discussion with the Medical Monitor. All patients will be followed for documentation of disease progression and survival information (i.e., date and cause of death) and subsequent treatment information (i.e., date/duration of treatment, response, and subsequent disease progression). Long-term follow-up will continue every 12 weeks (± 7 days) until the endpoint of death, the patient is lost to follow-up, or for 24 months following the final dose of study drug, whichever comes first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03307616 -
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
|
Phase 2 | |
| Completed |
NCT01913652 -
Ph II Cabazitaxel DD Liposarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06389799 -
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
|
Phase 2 | |
| Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT06115681 -
Real-world Study of Dedifferentiated Liposarcoma Patients in China
|
||
| Active, not recruiting |
NCT02846987 -
Study of Abemaciclib in Dedifferentiated Liposarcoma
|
Phase 2 | |
| Completed |
NCT02606461 -
Selinexor in Advanced Liposarcoma
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04242238 -
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
|
Phase 1 | |
| Withdrawn |
NCT00969917 -
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
| Terminated |
NCT03604783 -
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05496569 -
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
|
Phase 2 |